The regulator has asked Beam for a range of technical data before it can start testing the blood cancer treatment in humans.

The new shots, which are designed to better target circulating strains of omicron, could be available within days. Advisers to the CDC are set to meet later this week.

Drew Panayiotou led marketing efforts at Alphabet’s life sciences arm Verily, and his appointment is Pfizer’s third senior-level hire this year.

The commercial market for COVID-19 vaccinations could be similar to that for seasonal flu shots and other vaccines, an official with the department said.

The biotech's drug prospect vopratelimab has become the latest member of a group of medicines targeting a molecule called ICOS to fall short of expectations in clinical testing.  

The neuroscience-focused company has agreed to buy U.K.-based Diurnal for around $57 million, a move it expects to “accelerate the establishment of its clinical development and commercial activities” in Europe.

In a wide-ranging conversation with BioPharma Dive, Booth, a prolific builder of new biotechs, said he’s starting to see positive signs for startups considering an IPO or private financing.

With enough cash now to last two years, the company, which merged with a SPAC last week, hopes it can change the way children with ADHD are treated.

The new data position AstraZeneca to significantly expand use of Farxiga in heart failure and compete with Lilly and Boehringer Ingelheim’s rival drug Jardiance. 

Though the companies plan to move their medicines into late-stage testing, they each missed their main Phase 2 goals, raising questions about the prospects of so-called Factor XI inhibitors. 

Sold as Pemazyre, the drug, which blocks well-known cancer proteins known as FGFRs, is now also cleared for use in certain patients with very rare and aggressive blood cancers.

With regulators and lawmakers seemingly on board, sponsors have more opportunities than ever to pursue clinical research in this high-velocity area.